Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COVERA-HS vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Hypertension,Angina pectoris including chronic stable angina, vasospastic (Prinzmetal's) angina, and unstable angina,Supraventricular tachyarrhythmias including atrial fibrillation/flutter and paroxysmal supraventricular tachycardia
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Primarily hepatic metabolism via cytochrome P450 enzymes, including CYP3A4, CYP2C8, and CYP1A2, with extensive first-pass effect. Major metabolites include norverapamil (active) and various dealkylated and conjugated metabolites.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
95–98% bound to plasma proteins, primarily to albumin.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
2.0–2.5 L/kg, indicating extensive tissue distribution.
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 70–86% due to first-pass metabolism.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: start at 180 mg daily, titrate cautiously. Not dialyzable.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Safety and efficacy not established; no recommended dosing.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Start at 180 mg orally once daily; titrate slowly due to increased sensitivity and reduced clearance.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None
None.
May cause hypotension, especially in patients with ventricular dysfunction,Can precipitate heart failure or worsen pre-existing heart failure,Risk of bradycardia and heart block, especially in patients with sick sinus syndrome or pre-existing conduction defects,Caution in patients with hypertrophic cardiomyopathy due to risk of worsening obstruction and hypotension,Avoid abrupt withdrawal in patients with angina; may cause severe exacerbation,May increase serum levels of digoxin, cyclosporine, and other CYP3A4 substrates,Use with caution in patients with hepatic impairment due to reduced clearance,May cause symptomatic hypotension when administered with beta-blockers or other antihypertensives,Monitor for constipation, especially in elderly patients
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe left ventricular dysfunction (ejection fraction <30%),Hypotension (systolic blood pressure <90 mm Hg),Cardiogenic shock,Sick sinus syndrome (unless pacemaker in place),Second- or third-degree AV block (unless pacemaker in place),Atrial fibrillation/flutter with accessory bypass tract (e.g., Wolff-Parkinson-White syndrome),Known hypersensitivity to verapamil or any component of the formulation,Concurrent use of ivabradine
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid grapefruit and grapefruit juice; may increase verapamil serum concentrations. Limit alcohol intake; can potentiate hypotensive effects and increase risk of bradycardia. High-fat meals may delay absorption but do not significantly alter AUC; take consistently with food.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated with fetal hypotension, oligohydramnios, intrauterine growth restriction (IUGR), and hypocalcemia. May cause preterm delivery and neonatal renal impairment.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Verapamil (active ingredient) is excreted into human breast milk at low concentrations (M/P ratio ~0.6-0.8). Estimated infant dose is <0.1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for hypotonia, bradycardia, and constipation.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustments are routinely recommended; however, pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may necessitate dose titration based on clinical response. Consider using lowest effective dose to minimize fetal hypotension and hypoperfusion.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Covera-HS (verapamil extended-release) is formulated for bedtime dosing to maximize blood pressure control during early morning surge. Avoid use in patients with pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) due to risk of ventricular fibrillation. Monitor for constipation, especially in elderly. Adjust dose in hepatic impairment; contraindicated in severe left ventricular dysfunction and hypotension.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Take exactly as prescribed, usually once daily at bedtime, with food to minimize gastrointestinal irritation.,Swallow tablet whole; do not crush, chew, or break.,Do not discontinue abruptly; may cause rebound hypertension or angina.,Avoid grapefruit juice and alcohol; they can increase verapamil levels or enhance side effects.,Report symptoms such as slow heartbeat, dizziness, fainting, or swelling of ankles/feet.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COVERA-HS vs ACTIFED, answered by our medical review team.
COVERA-HS is a Calcium Channel Blocker that works by Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COVERA-HS and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COVERA-HS is: 180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COVERA-HS and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COVERA-HS is classified as Category C. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.